Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), announced that it received final U.S. Food & Drug Administration (FDA) approval for its application to manufacture and market a generic version of Bayer Pharmaceuticals Corporation’s Nimotop(R) (nimodipine) Capsules, 30 mg.
The Company will launch its product later this month.
Nimotop had annual sales of approximately $29 million for the twelve months ended February 2007, based on IMS sales data.
Nimotop (nimodipine) is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).